Skip to main content
    I

    INmune Bio Inc (INMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.96
    +0.01 (+1.44%)

    Market Cap: $29.30M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    INmune Bio Inc (INMB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    INmune Bio (INMB) has a market cap of $29.30M and an enterprise value of $12.97M. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $16.33M more cash than debt, 55.73% of its market cap.

    Total Valuation

    Enterprise value is 55.73% below the market cap, as cash exceeds debt.

    Market Cap$29.30M
    Enterprise Value$12.97M
    Latest price (Nov 17, 2026)$0.96

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.08% in the quarter ended Sep 30, 2026 and grew 17.37% a year over 2 years.

    Shares Outstanding27.81M
    Shares Change (YoY)+4.60%
    Shares Change (QoQ)+4.08%
    Share Count Growth (2Y CAGR)+17.37%

    Price Statistics

    The stock is down 32.39% over 52 weeks and trades 43.53% below its 50-day average.

    Beta (1Y)2.57
    52-Week Change-32.39%
    1-Month Change-37.66%
    3-Month Change-56.95%
    6-Month Change-31.91%
    5-Year Change-92.12%
    Total Return (1Y)-32.39%
    Total Return (3Y CAGR)-49.39%
    Total Return (5Y CAGR)-41.27%
    Max Drawdown (1Y)-62.29%
    Max Drawdown (3Y)-93.24%
    Sharpe Ratio (1Y)-0.60
    Correlation with SPY (1Y)0.48
    50-Day Average$1.70
    200-Day Average$1.61
    52-Week Range$0.89 to $2.60
    RSI (14 Days)20.4
    Average Volume (20 Days)335.59K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.41x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.41x
    Quick Ratio6.41x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -92.21% over the last 12 months, against a 5-year average of -97.99%.

    Return on Equity (ROE)-92.21%
    Return on Assets (ROA)-77.49%
    ROE (5Y Average)-97.99%
    ROA (5Y Average)-72.95%
    ROIC (5Y Average)-70.76%

    Scores

    INMB has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$56.00K
    Operating Income-$17.77M
    Pretax Income-$16.67M
    Net Income-$16.67M
    Reported EPS (TTM)-$0.60

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 84.01% of the $21.51M in total assets.

    Cash and Equivalents$16.33M
    Total Debt$0
    Net Cash$16.33M
    Net Cash Per Share$0.59
    Working Capital$15.79M
    Shareholder Equity$18.07M
    Book Value Per Share$0.65
    Total Assets$21.51M
    Total Liabilities$3.44M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$12.91M
    FCF Per Share-$0.42
    Depreciation and Amortization$247.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Revenue fell 48.87% a year over 3 years.

    Revenue Growth (3Y CAGR)-48.87%
    Revenue Growth (5Y CAGR)+35.37%
    Book Value Per Share Growth (2Y CAGR)-34.78%
    Tangible Book Per Share Growth (2Y CAGR)-12.67%

    Revenue and profit by year

    Dividends and Yields

    INMB does not pay a dividend.

    Buyback Yield-3.92%
    Shareholder Yield-3.92%

    Analyst Forecast

    Consensus estimates put revenue growth at 1642.41% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+1642.41%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About INMB

    What is INMB's market cap?

    INmune Bio has a market cap of $29.30M. Its enterprise value, which adds debt and subtracts cash, is $12.97M.

    How many shares of INMB are outstanding?

    INmune Bio has 27.81M shares outstanding. The count is up 4.60% from a year earlier.

    Does INMB pay a dividend?

    No. INmune Bio does not pay a dividend.

    How much debt does INMB have?

    INmune Bio has $0 of total debt and $16.33M of cash and equivalents, a net cash position of $16.33M.